The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi:10.1002/hep.30251
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. doi:10.1002/hep.23314
   PubMed Web of Science ®Google Scholar
• Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou P. Non-alcoholic fatty liver disease and vascular disease. Curr Vasc Pharmacol. 2021;19(3):269–279. doi:10.2174/1570161118666200318103001
   PubMed Web of Science ®Google Scholar
• Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-The-art. World J Gastroenterol. 2014;20(37):13306–13324. doi:10.3748/wjg.v20.i37.13306
   PubMed Web of Science ®Google Scholar
• Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 2003;163(16):1939–1942. doi:10.1001/archinte.163.16.1939
   PubMedGoogle Scholar
• Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. BMJ. 2018;360:j5842. doi:10.1136/bmj.j5842
   PubMedGoogle Scholar
• Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation. 2011;124(1):17–23. doi:10.1161/circulationaha.110.003954
   PubMed Web of Science ®Google Scholar
• Wang FM, Yang C, Ballew SH, et al. Ankle-brachial index and subsequent risk of incident and recurrent cardiovascular events in older adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2021;336:39–47. doi:10.1016/j.atherosclerosis.2021.09.028
   PubMed Web of Science ®Google Scholar
• Huang Y, Bi Y, Xu M, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32(9):2321–2326. doi:10.1161/atvbaha.112.252957
   PubMed Web of Science ®Google Scholar
• Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107(1):10–6.
   PubMed Web of Science ®Google Scholar
• Zou Y, Li X, Wang C, et al. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J. 2017;47(10):1147–1153. doi:10.1111/imj.13549
   PubMed Web of Science ®Google Scholar
• Liu S, Wang J, Wu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120:154779. doi:10.1016/j.metabol.2021.154779
   PubMed Web of Science ®Google Scholar
• Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–9.e4. doi:10.1053/j.gastro.2013.06.057
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/asn.2006040368
   PubMed Web of Science ®Google Scholar
• Chinese Diabetes Society. Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition). Zhonghua nei ke za zhi. 2022;61(1):12–50. Chinese. doi:10.3760/cma.j.cn112138-20211027-00751
   PubMedGoogle Scholar
• Liu LS, Wu ZS, Wang JG, et al. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the Revision Committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182–241. doi:10.11909/j.issn.1671-5411.2019.03.014
   PubMedGoogle Scholar
• Joint Committee for Developing Chinese guidelines on P. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua xin xue guan bing za zhi. 2007;35(5):390–419. Chinese.
   PubMedGoogle Scholar
• Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775–777. doi:10.1111/j.1440-1746.2007.05002.x
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi:10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Alves-Cabratosa L, Elosua-Bayes M, García-Gil M, et al. Hypertension and high ankle brachial index: the overlooked combination. J Hypertens. 2019;37(1):92–98. doi:10.1097/hjh.0000000000001861
   PubMed Web of Science ®Google Scholar
• Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88(3):837–845. doi:10.1161/01.cir.88.3.837
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco JB, Bartelink MEL, et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi:10.1093/eurheartj/ehx095
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–743. doi:10.1161/01.Cir.0000137913.26087.F0
   PubMed Web of Science ®Google Scholar
• He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg. 2006;44(2):333–338. doi:10.1016/j.jvs.2006.03.032
   PubMed Web of Science ®Google Scholar
• Chuang SY, Chen CH, Cheng CM, Chou P. Combined use of brachial-ankle pulse wave velocity and ankle-brachial index for fast assessment of arteriosclerosis and atherosclerosis in a community. Int J Cardiol. 2005;98(1):99–105. doi:10.1016/j.ijcard.2004.01.019
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Xu YW, et al. Prevalence of peripheral arterial disease and correlative risk factors among natural population in China. Zhonghua xin xue guan bing za zhi. 2009;37(12):1127–1131. Chinese.
   PubMedGoogle Scholar
• Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. doi:10.1016/j.jhep.2016.05.013
   PubMed Web of Science ®Google Scholar
• Guleria A, Duseja A, Kalra N, et al. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol. 2013;34(2):74–82. doi:10.7869/tg.2012.101
   PubMedGoogle Scholar
• Liu Y, Liu C, Shi X, et al. Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults. J Diabetes. 2017;9(6):586–595. doi:10.1111/1753-0407.12441
   PubMed Web of Science ®Google Scholar
• Conte SM, Vale PR. Peripheral arterial disease. Heart Lung Circ. 2018;27(4):427–432. doi:10.1016/j.hlc.2017.10.014
   PubMed Web of Science ®Google Scholar
• Hong HC, Hwang SY, Ryu JY, et al. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis. Clin Endocrinol. 2016;84(2):203–209. doi:10.1111/cen.12940
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431. doi:10.7326/0003-4819-141-6-200409210-00007
   PubMed Web of Science ®Google Scholar
• Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. Circ Res. 2021;128(12):1818–1832. doi:10.1161/circresaha.121.318535
   PubMed Web of Science ®Google Scholar
• Golledge J, Ward NC, Watts GF. Lipid management in people with peripheral artery disease. Curr Opin Lipidol. 2019;30(6):470–476. doi:10.1097/mol.0000000000000638
   PubMed Web of Science ®Google Scholar
• Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015;27(3):193–199. doi:10.1097/meg.0000000000000254
   PubMed Web of Science ®Google Scholar
• Cai J, Xu M, Zhang X, Li H. Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases. Annu Rev Pathol. 2019;14:153–184. doi:10.1146/annurev-pathmechdis-012418-013003
   PubMed Web of Science ®Google Scholar
• Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212–20. doi:10.1002/ccd.25387
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Scuto S, Marino E, Xourafa A, Gaudio A. Oxidative stress in Peripheral Arterial Disease (PAD) mechanism and biomarkers. Antioxidants. 2019;8(9):367. doi:10.3390/antiox8090367
   Web of Science ®Google Scholar
• Britton KA, Mukamal KJ, Ix JH, et al. Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study. Vasc Med. 2012;17(2):85–93. doi:10.1177/1358863x11436195
   PubMed Web of Science ®Google Scholar
• Yang SL, Zhu LY, Han R, Sun LL, Li JX, Dou JT. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes. 2017;9(2):133–140. doi:10.1111/1753-0407.12474
   PubMed Web of Science ®Google Scholar
• Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes. 2021;9(1):135. doi:10.3390/pr9010135
   Web of Science ®Google Scholar
• Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021;10(2):270. doi:10.3390/antiox10020270
   Web of Science ®Google Scholar
• Li W, Liu J, Cai J, et al. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol. 2022;163:118–132. doi:10.1016/j.yjmcc.2021.10.007
   PubMed Web of Science ®Google Scholar
• Tilg H, From EM. NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387–388. doi:10.1038/s41575-020-0316-6
   PubMed Web of Science ®Google Scholar
• Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136–1150. doi:10.1016/j.metabol.2015.09.017
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• Gao L, Zhao W, Liu Q, Qin M. Association between metabolic syndrome and peripheral arterial disease in elderly patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2021;14:4783–4789. doi:10.2147/dmso.S343441
   PubMed Web of Science ®Google Scholar
• Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3(1):33–40. doi:10.1046/j.1463-1326.2001.00103.x
   PubMed Web of Science ®Google Scholar
• Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. doi:10.1016/j.metabol.2021.154925
   PubMed Web of Science ®Google Scholar